Therapeutic Potential of Pigment Epithelium-derived Factor in Cancer.
Angiogenesis
PEDF
apoptosis
cancer
inflammation
tissue homeostasis.
Journal
Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
02
2019
accepted:
13
03
2019
pubmed:
21
3
2019
medline:
23
2
2020
entrez:
21
3
2019
Statut:
ppublish
Résumé
Pigment epithelium-derived factor (PEDF) is one of the serine protease inhibitors with multifunctional properties, which is produced by various types of organs and tissues. There is an accumulating body of evidence that PEDF plays an important role in the maintenance of tissue homeostasis. Indeed, PEDF not only works as an endogenous inhibitor of angiogenesis, but also suppresses oxidative stress, inflammatory and thrombotic reactions in cell culture systems, animal models, and humans. Furthermore, we, along with others, have found that PEDF inhibits proliferation of, and induces apoptotic cell death in, numerous kinds of tumors. In addition, circulating as well as tumor expression levels of PEDF have been inversely associated with tumor growth and metastasis. These observations suggest that supplementation of PEDF proteins and/or enhancement of endogenous PEDF expression could be a novel therapeutic strategy for the treatment of cancer. Therefore, in this paper, we review the effects of PEDF on diverse types of cancer, and discuss its therapeutic perspectives.
Identifiants
pubmed: 30892156
pii: CPD-EPUB-97413
doi: 10.2174/1381612825666190319112106
doi:
Substances chimiques
Eye Proteins
0
Nerve Growth Factors
0
Serpins
0
pigment epithelium-derived factor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
313-324Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.